Do you want to read an article? Please log in or register.
HER2 mediates clinical resistance to the KRASG12C inhibitor sotorasib, which is overcome by co-targeting SHP2
Lung, Respiratory and Thoracic Cancer
Related content
Breast Cancer
Recent Developments in Metastatic Breast Cancer
healthbook TIMES Oncology Hematology
RECOMMENDED
Lung, Respiratory and Thoracic Cancer
Targeting c-Myc to overcome acquired resistance of EGFR mutant NSCLC cells to the third generation EGFR tyrosine kinase inhibitor, osimertinib
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Cancer Res
Zhu L, Chen Z, Zang H, Fan S, Gu J, Zhang G, Sun KD, Wang Q, He Y, Owonikoko TK, Ramalingam SS, Sun SY
doi: 10.1158/0008-5472.CAN-21-0556
RECOMMENDED
Lung, Respiratory and Thoracic Cancer
Targeting c-Myc to overcome acquired resistance of EGFR mutant NSCLC cells to the third generation EGFR tyrosine kinase inhibitor, osimertinib
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Cancer Res
Zhu L, Chen Z, Zang H, Fan S, Gu J, Zhang G, Sun KD, Wang Q, He Y, Owonikoko TK, Ramalingam SS, Sun SY
doi: 10.1158/0008-5472.CAN-21-0556
Gynecologic Cancer
PARP inhibitors: Clinical utility and possibilities of overcoming resistance
Gynecol Oncol.
Bitler BG, Watson ZL, Wheeler LJ, Behbakht K
doi: 10.1016/j.ygyno.2017.10.003.
SPECIAL REPORT
Multiple Myeloma (MM)
Therapie des rezidivierten/refraktären Multiplen Myeloms
RECOMMENDED
Lung, Respiratory and Thoracic Cancer
Activity of a novel HER2 inhibitor, poziotinib, for HER2 exon 20 mutations in lung cancer and mechanism of acquired resistance: An in vitro study
Lung Cancer.
Koga T, Kobayashi Y, Tomizawa K, Suda K, Kosaka T, Sesumi Y, Fujino T, Nishino M, Ohara S, Chiba M, Shimoji M, Takemoto T, Suzuki M, Jänne PA, Mitsudomi T
doi: 10.1016/j.lungcan.
Lung, Respiratory and Thoracic Cancer
Overcoming EGFRG724S-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors
Nat Commun.
Fassunke J, Müller F, Keul M, Michels S, Dammert MA, Schmitt A, Plenker D, Lategahn J, Heydt C, Brägelmann J, Tumbrink HL, Alber Y, Klein S, Heimsoeth A, Dahmen I, Fischer RN, Scheffler M, Ihle MA, Priesner V, Scheel AH, Wagener S, Kron A, Frank K, Garbert K, Persigehl T, Püsken M, Haneder S, Schaaf B, Rodermann E, Engel-Riedel W, Felip E, Smit EF, Merkelbach-Bruse S, Reinhardt HC, Kast SM, Wolf J, Rauh D, Büttner R, Sos ML
doi: 10.1038/s41467-
Lung Cancer
Molecular Diagnostic and Precision Medicine in Non-Small Cell Lung Cancer. An Update on the Treatment of the Most Important Actionable Oncogenic Driver Alterations.
1Department of Medical Oncology, University Hospital Basel, Basel, Switzerland.
RECOMMENDED
Lung, Respiratory and Thoracic Cancer
KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors
★ 1
Recommended by
Dr Wolf-Dieter Janthur, Faculty Member
★ 3
Recommended by
Dr Martin Frey, Faculty Member
N Engl J Med.
Hong DS, Fakih MG, Strickler JH, Desai J, Durm GA, Shapiro GI, Falchook GS, Price TJ, Sacher A, Denlinger CS, Bang YJ, Dy GK, Krauss JC, Kuboki Y, Kuo JC, Coveler AL, Park K, Kim TW, Barlesi F, Munster PN, Ramalingam SS, Burns TF, Meric-Bernstam F, Henary H, Ngang J, Ngarmchamnanrith G, Kim J, Houk BE, Canon J, Lipford JR, Friberg G, Lito P, Govindan R, Li BT
doi: 10.1056/NEJMoa1917239.